[{"orgOrder":0,"company":"RVL Pharmaceuticals","sponsor":"Osmotica Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Baclofen","moa":"GABA-B receptor","graph1":"Neurology","graph2":"Phase III","graph3":"RVL Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"RVL Pharmaceuticals \/ Osmotica Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"RVL Pharmaceuticals \/ Osmotica Pharmaceuticals"},{"orgOrder":0,"company":"RVL Pharmaceuticals","sponsor":"Osmotica Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Baclofen","moa":"GABA-B receptor","graph1":"Neurology","graph2":"Phase III","graph3":"RVL Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"RVL Pharmaceuticals \/ Osmotica Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"RVL Pharmaceuticals \/ Osmotica Pharmaceuticals"},{"orgOrder":0,"company":"RVL Pharmaceuticals","sponsor":"Osmotica Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Baclofen","moa":"GABA-B receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"RVL Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"RVL Pharmaceuticals \/ Osmotica Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"RVL Pharmaceuticals \/ Osmotica Pharmaceuticals"},{"orgOrder":0,"company":"RVL Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Baclofen","moa":"GABA-B receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"RVL Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"RVL Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RVL Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"RVL Pharmaceuticals","sponsor":"Osmotica Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Baclofen","moa":"GABA-B receptor","graph1":"Neurology","graph2":"Phase III","graph3":"RVL Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"RVL Pharmaceuticals \/ Osmotica Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"RVL Pharmaceuticals \/ Osmotica Pharmaceuticals"},{"orgOrder":0,"company":"Seaside Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Baclofen","moa":"GABA-B receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Seaside Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Seaside Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Seaside Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seaside Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Baclofen","moa":"GABA-B receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Seaside Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Seaside Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Seaside Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seaside Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Baclofen","moa":"GABA-B receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Seaside Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Seaside Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Seaside Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seaside Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Baclofen","moa":"GABA-B receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Seaside Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seaside Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Seaside Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seaside Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Baclofen","moa":"GABA-B receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Seaside Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seaside Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Seaside Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seaside Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Baclofen","moa":"GABA-B receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Seaside Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seaside Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Seaside Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"RVL Pharmaceuticals","sponsor":"Osmotica Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Baclofen","moa":"GABA-B receptor","graph1":"Neurology","graph2":"Phase III","graph3":"RVL Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RVL Pharmaceuticals \/ Osmotica Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"RVL Pharmaceuticals \/ Osmotica Pharmaceuticals"},{"orgOrder":0,"company":"Seaside Therapeutics","sponsor":"Allos Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"Baclofen","moa":"GABA-B receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Seaside Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Seaside Therapeutics \/ Allos Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Seaside Therapeutics \/ Allos Pharma"},{"orgOrder":0,"company":"Evdokia Anagnostou","sponsor":"Holland Bloorview Kids Rehabilitation Hospital | McMaster University | University of Western Ontario, Canada | Queen's University | Unity Health Toronto | University of Toronto","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Baclofen","moa":"GABA-B receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Evdokia Anagnostou","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evdokia Anagnostou \/ Holland Bloorview Kids Rehabilitation Hospital | McMaster University | University of Western Ontario, Canada | Queen's University | Unity Health Toronto | University of Toronto","highestDevelopmentStatusID":"8","companyTruncated":"Evdokia Anagnostou \/ Holland Bloorview Kids Rehabilitation Hospital | McMaster University | University of Western Ontario, Canada | Queen's University | Unity Health Toronto | University of Toronto"},{"orgOrder":0,"company":"Unichem Laboratories Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"INDIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Baclofen","moa":"GABA-B receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Unichem Laboratories Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Unichem Laboratories Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Unichem Laboratories Limited \/ Undisclosed"},{"orgOrder":0,"company":"University Hospital, Lille","sponsor":"R\u00e9gion Nord-Pas de Calais, France | Groupement Interr\u00e9gional de Recherche Clinique et d'Innovation","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Baclofen","moa":"GABA-B receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"University Hospital, Lille","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital, Lille \/ R\u00e9gion Nord-Pas de Calais, France | Groupement Interr\u00e9gional de Recherche Clinique et d'Innovation","highestDevelopmentStatusID":"11","companyTruncated":"University Hospital, Lille \/ R\u00e9gion Nord-Pas de Calais, France | Groupement Interr\u00e9gional de Recherche Clinique et d'Innovation"},{"orgOrder":0,"company":"Institut Guttmann","sponsor":"Medtronic Plc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SPAIN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Baclofen","moa":"GABA-B receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Institut Guttmann","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Institut Guttmann \/ Medtronic plc","highestDevelopmentStatusID":"1","companyTruncated":"Institut Guttmann \/ Medtronic plc"},{"orgOrder":0,"company":"Pharnext","sponsor":"Alpha Blue Ocean","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Financing","leadProduct":"Baclofen","moa":"||GABA-B receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharnext","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.10000000000000001,"dosageForm":"Solution","sponsorNew":"Pharnext \/ Alpha Blue Ocean","highestDevelopmentStatusID":"10","companyTruncated":"Pharnext \/ Alpha Blue Ocean"},{"orgOrder":0,"company":"Pharnext","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Baclofen","moa":"||GABA-B receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharnext","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution","sponsorNew":"Pharnext \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pharnext \/ Undisclosed"},{"orgOrder":0,"company":"Pharnext","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Baclofen","moa":"||GABA-B receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharnext","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution","sponsorNew":"Pharnext \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pharnext \/ Undisclosed"},{"orgOrder":0,"company":"Pharnext","sponsor":"Neovacs","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Financing","leadProduct":"Baclofen","moa":"||GABA-B receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharnext","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Solution","sponsorNew":"Pharnext \/ Neovacs","highestDevelopmentStatusID":"10","companyTruncated":"Pharnext \/ Neovacs"},{"orgOrder":0,"company":"Pharnext","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Baclofen","moa":"||GABA-B receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharnext","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution","sponsorNew":"Pharnext \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pharnext \/ Undisclosed"},{"orgOrder":0,"company":"Pharnext","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Baclofen","moa":"||GABA-B receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharnext","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution","sponsorNew":"Pharnext \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pharnext \/ Undisclosed"},{"orgOrder":0,"company":"Pharnext","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Baclofen","moa":"||GABA-B receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharnext","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution","sponsorNew":"Pharnext \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pharnext \/ Undisclosed"},{"orgOrder":0,"company":"Pharnext","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Baclofen","moa":"||GABA-B receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharnext","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution","sponsorNew":"Pharnext \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pharnext \/ Undisclosed"},{"orgOrder":0,"company":"Pharnext","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Baclofen","moa":"||GABA-B receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharnext","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution","sponsorNew":"Pharnext \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pharnext \/ Undisclosed"},{"orgOrder":0,"company":"Ethypharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Baclofen","moa":"GABA-B receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Ethypharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ethypharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ethypharm \/ Undisclosed"},{"orgOrder":0,"company":"Gedeon Richter","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"HUNGARY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Baclofen","moa":"GABA-B receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Gedeon Richter","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gedeon Richter \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Gedeon Richter \/ Undisclosed"},{"orgOrder":0,"company":"Centre for Addiction and Mental Health","sponsor":"Canadian Tobacco Control Research Initiative","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Baclofen","moa":"GABA-B receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Centre for Addiction and Mental Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre for Addiction and Mental Health \/ Canadian Tobacco Control Research Initiative","highestDevelopmentStatusID":"8","companyTruncated":"Centre for Addiction and Mental Health \/ Canadian Tobacco Control Research Initiative"},{"orgOrder":0,"company":"Dr. John A. Thiel Medical Professional Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Baclofen","moa":"GABA-B receptor","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"Dr. John A. Thiel Medical Professional Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dr. John A. Thiel Medical Professional Corporation \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Dr. John A. Thiel Medical Professional Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Essentia Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Baclofen","moa":"GABA-B receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Essentia Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Essentia Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Essentia Health \/ Undisclosed"},{"orgOrder":0,"company":"Vanderbilt University","sponsor":"Medtronic Plc","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Baclofen","moa":"GABA-B receptor","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Vanderbilt University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vanderbilt University \/ Medtronic plc","highestDevelopmentStatusID":"11","companyTruncated":"Vanderbilt University \/ Medtronic plc"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Baclofen","moa":"||GABA-B receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Granules","sponsorNew":"Amneal Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Piramal Pharma Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Baclofen","moa":"GABA-B receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Piramal Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Piramal Pharma Solutions \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Piramal Pharma Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Saol therapeutics","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Acquisition","leadProduct":"Baclofen","moa":"GABA-B receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Saol therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Saol therapeutics \/ Amneal Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Saol therapeutics \/ Amneal Pharmaceuticals"},{"orgOrder":0,"company":"Nexus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Baclofen","moa":"GABA-B receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Nexus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nexus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Nexus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Charcot Marie Tooth Association","sponsor":"Pharnext","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Baclofen","moa":"||GABA-B receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Charcot Marie Tooth Association","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution","sponsorNew":"Charcot Marie Tooth Association \/ Pharnext","highestDevelopmentStatusID":"10","companyTruncated":"Charcot Marie Tooth Association \/ Pharnext"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Baclofen","moa":"GABA-B receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"ANI Pharmaceuticals Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Undisclosed"},{"orgOrder":0,"company":"Allos Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Baclofen","moa":"GABA-B receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Allos Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Allos Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allos Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Allos Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Baclofen","moa":"GABA-B receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Allos Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Allos Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allos Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Seaside Therapeutics","sponsor":"Allos Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Baclofen","moa":"GABA-B receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Seaside Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Seaside Therapeutics \/ Allos Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Seaside Therapeutics \/ Allos Pharma"},{"orgOrder":0,"company":"Osmotica Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Baclofen","moa":"GABA-B receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Osmotica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Osmotica Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Osmotica Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Osmotica Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Baclofen","moa":"GABA-B receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Osmotica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Osmotica Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Osmotica Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"South West Sydney Local Health District","sponsor":"National Health and Medical Research Council, Australia | University of Sydney","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"AUSTRALIA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Baclofen","moa":"GABA-B receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"South West Sydney Local Health District","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"South West Sydney Local Health District \/ National Health and Medical Research Council, Australia | University of Sydney","highestDevelopmentStatusID":"10","companyTruncated":"South West Sydney Local Health District \/ National Health and Medical Research Council, Australia | University of Sydney"},{"orgOrder":0,"company":"Allaysis","sponsor":"University of Minnesota","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Baclofen","moa":"GABA-B receptor","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Allaysis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Allaysis \/ University of Minnesota","highestDevelopmentStatusID":"7","companyTruncated":"Allaysis \/ University of Minnesota"},{"orgOrder":0,"company":"Seaside Therapeutics","sponsor":"Joseph Gonzalez-Heydrich","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Baclofen","moa":"GABA-B receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Seaside Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seaside Therapeutics \/ Joseph Gonzalez-Heydrich","highestDevelopmentStatusID":"6","companyTruncated":"Seaside Therapeutics \/ Joseph Gonzalez-Heydrich"}]
Find Clinical Drug Pipeline Developments & Deals for (?)-Baclofen
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
Ethypharm is an international Pharma company with European roots manufacturing and commercializing essential drugs all over the world.
